Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board

Biophytis announced the appointment of Dr Yann Meunier and Professor Bernard Lévy to its Scientific Advisory Board.

Yann Meunier is a US-based healthcare professional, currently Professor and Director of the International Institute of Medicine and Science, Inc (IIMS), where he leads the development and implementation of innovative educational programmes and research projects in global health and related fields. He is also a consultant and health expert with HealthConnect International LLC. Over the course of his career, he has worked with leading organisations such as Stanford Hospital & Clinics, Stanford University School of Medicine, George Washington University and Université Paris VI. He has published widely in the international medical literature and, as an investigator, has led and participated in clinical trials for new treatments for HIV/AIDS, tropical and infectious diseases, and cardiovascular and respiratory diseases.

Bernard Lévy is Professor Emeritus of Physiology and a senior member of PARCC (Inserm U970). He headed the physiology and functional investigations department and the Inserm cardiovascular research centre at Lariboisière Hospital in Paris. After studying medicine, he focused on physiology, fluid mechanics, cardiology and vascular medicine. His work focuses on vascular biology in ageing, hypertension, diabetes and Alzheimer’s disease, and he has particularly studied the functions of the renin-angiotensin system in these different diseases.

Stanislas Veillet, CEO of Biophytis, commented: “We are delighted to welcome two important new members to our Scientific Advisory Board, who will be able to contribute actively to the discussions and reflections on Biophytis’ strategy and the development plans for our drug candidates in their various indications. In particular, Bernard Lévy will bring us his in-depth knowledge of the renin-angiotensin system, a key system for the proper functioning of muscular and cardio-respiratory functions, which we are specifically targeting with our drug candidate BIO101. For his part, Yann Meunier, the infectiologist behind the discovery of HIV, will be contributing his expertise in respiratory infections, which are still a major public health problem today. This high-level scientific support is crucial to positioning BIO101 as effectively as possible, particularly in its most advanced indications of COVID-19 and sarcopenia.”